Myriad Genetics, Inc. (MYGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 02:05PM EST. Market open.
| Previous Close | 25.53 |
| Open | 25.42 |
| Bid | 26.46 x 900 |
| Ask | 33.44 x 800 |
| Day's Range | 25.42 - 26.61 |
| 52 Week Range | 17.32 - 36.95 |
| Volume | |
| Avg. Volume | 437,130 |
| Market Cap | 2.048B |
| Beta (5Y Monthly) | 1.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.
- Motley Fool
Myriad Genetics, Inc (MYGN) Q3 2021 Earnings Call Transcript
During the call, we will review the financial results we released today and after which we will host a question-and-answer session. On the call with me today are Paul Diaz, our President and Chief Executive Officer and Bryan Riggsbee, our Chief Financial Officer.
- Zacks
Myriad Genetics (MYGN) Reports Q3 Loss, Tops Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -300.00% and 1.80%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
